The latest international research shows that supplementation of hydrogen molecules as an aid, adjuvant, can speed up the course of the disease. The purpose of this study is to determine the safety and possible efficacy of hydrogen supplements in different dose exposures for a clinical study in rheumatologic and metabolic patients. Patients will receive a different dosage of hydrogen capsules with their conventional treatment for a month. Investigators will test for any changes in haematologic, urine analysis and health status during and following the exposure period.
According to the current literature, there is a lack of specific drugs for chronic inflammatory symptoms which develop from many refractory diseases with complicated clinical features. Hydrogen supplement has been shown to have significant removal effects on free radicals and reduce chronic inflammation. With these benefits, molecular hydrogen may have the ability to speed up the recovering the disease. The purpose of this study is to determine the safety and possible efficacy of hydrogen supplements in the different doses of hydrogen capsules for a clinical study in rheumatologic and metabolic patients. Study design: 15 rheumatologic patients and 15 metabolic patients will be recruited from the Min-Sheng General Hospital for this study. Participants will be screened by doctors for their eligibility and undergo a series of tests (questionnaires and examinations). Consenting participants will then be allocated into 3 groups by different dosage (Low, n=5; Medium, n=5; High, n=5). Participants will receive 1 (Low), 3 (Medium) or 6 (High) capsules every day for one month. Participants will be examined their regular haematology, urine and health status before and after the intervention.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
30
Participants take either 1 (n=5), 3 (n=5) or 6 (n=5) capsules every day for one month.
Min-Sheng Gereral hospital
Taoyuan, Taiwan
RECRUITINGAdverse effects/symptoms
Any adverse effects will be codified according the the NCI CTCAE v5.0
Time frame: up to 28 days
Change in physiological parameter (Blood Routine)
Numerical change in Blood Routine
Time frame: Change from Baseline Blood Routine at Day 28
Change in physiological parameter (Urine Routine)
Numerical change in Urine Routine
Time frame: Change from Baseline Urine Routine at Day 28
Brief Fatigue Inventory-Taiwan (BFI-T) (6 questions)
Questionnaire for rheumatologic patients minimum values:0 maximum values:60 Higher scores mean a worse outcome.
Time frame: Change from Baseline BFI-T at Day 28
Control status scale for diabetics (CSSD70) (First part: 11 questions)
Questionnaire for metabolic patients minimum values:0 maximum values:22 Higher scores mean a worse outcome.
Time frame: Change from Baseline CSSD70 at Day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.